Ribometrix and Genentech Partner in Potential $1 Billion+ RNA Deal
The Pharma Data
JANUARY 5, 2021
Targeting RNA is believed to be a way to develop therapeutics for so-called undruggable proteins. This is because many proteins do not have small-molecule binding sites. So therapeutics that focus on RNA are designed to stop the DNA from coding for disease-causing proteins.
Let's personalize your content